Business Context and Reporting Period
Company: Glucotrack, Inc. (GCTK)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Glucotrack is a medical device company developing an implantable continuous blood glucose monitor (CBGM) for Type 1 and Type 2 diabetes patients. The company has no commercial revenue and is focused on clinical development, having completed a first-in-human study in 2025 and submitted an Investigational Device Exemption (IDE) to the FDA subsequent to the reporting period.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,334) | $(6,833) |
| Loss Per Share (Basic & Diluted) | $(2.65) | $(40.14) |
| Cash and Cash Equivalents (End of Period) | $3,929 | $9,110 |
| Net Cash Used in Operating Activities | $(4,048) | $(2,939) |
| Total Assets | $4,356 | $7,838 |
| Total Liabilities | $5,207 | $5,010 |
| Stockholders' Equity (Deficit) | $(851) | $2,828 |
| Promissory Notes (Current) | $3,330 | $3,182 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $2.5 million (37%) compared to Q1 2025, primarily due to a significant reduction in the change in fair value of derivative liabilities (from a $3.376 million expense in 2025 to a $1 thousand gain in 2026).
- Operating Expenses: Total operating expenses increased to $4.203 million from $3.498 million. Research and Development (R&D) rose by $261 thousand due to product design and pre-clinical studies, while General and Administrative (G&A) expenses increased by $444 thousand due to higher professional fees and personnel costs.
- Liquidity Decline: Cash balances dropped by $3.454 million during the quarter, driven by operating cash outflows of $4.048 million, partially offset by $591 thousand in financing proceeds.
- Equity Position: The company moved from positive equity ($2.828 million) in Q1 2025 to a deficit of $(851) thousand in Q1 2026, reflecting the accumulated deficit of $156.172 million.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern. Current cash reserves are insufficient to fund operations for the next 12 months, necessitating additional equity or debt financing.
- Delisting Risk: On May 11, 2026, Nasdaq notified the company of a determination to delist its common stock due to failure to maintain a minimum bid price of $1.00 for 30 consecutive days. The company is ineligible for a standard compliance period due to recent reverse stock splits and intends to appeal the decision.
- Financing Activities: The company raised $590 thousand via an Equity Line of Credit (ELOC) in March 2026. Subsequent to the quarter, the company exchanged portions of its promissory notes for common stock and raised additional funds via the ELOC.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding IT controls, segregation of duties, and accounting personnel. Remediation efforts include implementing Oracle NetSuite and hiring additional staff.
- Product Development: The company closed a long-term feasibility study in Australia but has submitted an IDE for a U.S. clinical study. It maintains ISO 13485 certification.
Investor Verification Checklist
- Capital Adequacy: Verify the company's ability to secure immediate financing given the "substantial doubt" going concern warning and the cash burn rate of ~$4 million per quarter.
- Nasdaq Status: Monitor the outcome of the appeal against the Nasdaq delisting determination and the potential impact on stock liquidity and trading venue.
- Debt Obligations: Review the terms of the $3.33 million promissory note and the recent debt-for-equity exchange agreements to understand dilution risks and remaining debt service requirements.
- Clinical Milestones: Confirm the status of the U.S. IDE application and the timeline for the commencement of the new clinical trial.
- Internal Controls: Assess the progress of remediation plans for material weaknesses in financial reporting, which could impact future filing reliability.